{"id":640291,"date":"2026-10-24T20:58:09","date_gmt":"2026-10-24T20:58:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/640291\/"},"modified":"2026-10-24T20:58:09","modified_gmt":"2026-10-24T20:58:09","slug":"idweek-2026-infectious-disease-advisor","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/640291\/","title":{"rendered":"[IDWeek 2026] Infectious Disease Advisor"},"content":{"rendered":"<p> Infectious Disease Advisor news story<\/p>\n<p>Doravirine\/islatravir (DOR\/ISL) and bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) are associated with similar improvements in self-reported health status and reductions in bothersome symptoms among previously untreated adults with HIV-1, according to study results presented at IDWeek 2026, held from October 21 to 24, in Washington, DC.<\/p>\n<p class=\"wp-block-paragraph\">Researchers assessed patient-reported outcomes with DOR\/ISL, a novel 2-drug antiretroviral therapy (ART) regimen, compared with BIC\/FTC\/TAF in a double-blind phase 3 trial (ClinicalTrials.gov Identifier: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05705349\" target=\"_blank\" rel=\"noopener nofollow\">NCT05705349<\/a>). The trial previously demonstrated noninferior virologic efficacy and comparable safety between ART regimens at week 48.<\/p>\n<p>Read the full news story <a href=\"https:\/\/www.infectiousdiseaseadvisor.com\/reports\/doravirine-islatravir-patient-outcomes-hiv\/\" target=\"_blank\" rel=\"noopener nofollow\">here<\/a>.<\/p>\n<p>\/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month\/<\/p>\n<p><a href=\"https:\/\/www.infectiousdiseaseadvisor.com\/conferences\/id-week\/\" target=\"_blank\" rel=\"noopener nofollow\">View all Infectious Disease Advisor reports from IDWeek 2026<\/a><\/p>\n<p>\u00a0<\/p>\n<p>Source : <a href=\"https:\/\/www.infectiousdiseaseadvisor.com\/reports\/doravirine-islatravir-patient-outcomes-hiv\/\" target=\"_blank\" rel=\"nofollow noopener\">Infectious Disease Advisor<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Infectious Disease Advisor news story Doravirine\/islatravir (DOR\/ISL) and bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) are associated with similar improvements in self-reported&hellip;\n","protected":false},"author":2,"featured_media":640292,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[134,111,139,69],"class_list":["post-640291","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/640291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=640291"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/640291\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/640292"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=640291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=640291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=640291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}